Skip to main content
. 2020 May 22;3:114–125. doi: 10.1016/j.xjon.2020.05.003

Table 2.

Demographic, preoperative, and procedure comparisons

Demographic characteristics Unadjusted values
Inverse probability of treatment- weighted values
EACA (n = 778) TXA (n = 824) P value EACA (n = 778) TXA (n = 824) P value
Atrial fibrillation/flutter, n (%) 164 (21%) 138 (17%) .03 19% 19% .90
Aortic procedure, n (%) 76 (10%) 78 (9%) .90 10% 10% .51
Congestive heart failure, n (%) 259 (33%) 343 (42%) .0007 38% 38% .97
Cardiogenic shock, n (%) 23 (3%) 10 (1%) .02 2% 2% .87
Chronic lung disease, n (%) 190 (24%) 152 (18%) .004 21% 21% .92
Circulatory arrest during operation, n (%) 24 (3%) 25 (3%) 1.00 3% 3% .74
Diabetes, n (%) 264 (34%) 297 (36%) .41 35% 36% .31
Female sex, n (%) 219 (28%) 235 (29%) .91 29% 29% .95
Anticoagulation (coumadin, heparin), n (%) 373 (48%) 361 (44%) .11 46% 46% .88
Hypertension, n (%) 616 (79%) 662 (80%) .64 79% 80% .46
Left ventricular assist device, n (%) 4 (0.5%) 0 (0%) .06 0.6% 0% .003
Thrombolytic, n (%) 2 (0.3%) 8 (1%) .11 0.6% 0.6% .87
Peripheral vascular disease, n (%) 104 (13%) 114 (14%) .84 13% 14% .73
Cerebrovascular disease (CVA, TIA), n (%) 98 (13%) 82 (10%) .11 11% 11% .93
Antiplatelet therapy, n (%)
 Aspirin 681 (88%) 766 (93%) .0003 90% 90% .74
 GP IIb/IIIa inhibitor 7 (1%) 16 (2%) .12 1% 1% .86
 ADP receptor inhibitor 23 (3%) 31 (4%) .45 4% 3% .71
Preoperative dialysis, n (%) 13 (2%) 18 (2%) .57 2% 2% .84
Previous acute myocardial infarction, n (%) 344 (44%) 375 (46%) .67 44% 46% .23
Previous cardiac surgery, n (%) 57 (7%) 44 (5%) .13 6% 6% .97
Statin therapy, n (%) 617 (79%) 656 (80%) .93 80% 79% .59
Priority, n (%) .25 1.00
 Elective 354 (46%) 360 (44%) 44% 44%
 Emergent 43 (6%) 34 (4%) 5% 5%
 Urgent 381 (49%) 430 (52%) 51% 51%
Steroids, n (%) 21 (3%) 27 (3%) .60 2% 3% .27
Surgeon, n (%) <.0001 <.0001
 1 189 (24%) 236 (29%) 27% 28%
 2 232 (30%) 100 (12%) 29% 12%
 3 182 (23%) 176 (21%) 22% 23%
 4 175 (22%) 201 (24%) 23% 23%
 5 0 (0%) 103 (13%) 0% 12%
 6 0 (0%) 8 (1%) 0% 1%
Surgery type, n (%) .77 1.00
 Isolated CABG 423 (54%) 443 (54%) 54% 54%
 Isolated valve 123 (16%) 136 (17%) 16% 16%
 CABG/single valve 77 (10%) 92 (11%) 11% 11%
 Other 155 (20%) 153 (19%) 19% 19%
Hemoglobin A1C (%), median (IQR) 5.9 (5.6, 6.6) 5.9 (5.6, 6.7) .90 5.9 (5.6, 6.6) 5.9 (5.6, 6.7) 1.00
Age, y, median (IQR) 67 (58, 74) 67 (59, 74) .75 67 (58, 74) 67 (59, 74) 1.00
Body surface area, kg/m2, median (IQR) 2.0 (1.9, 2.2) 2.0 (1.9, 2.2) .31 2.0 (1.9, 2.2) 2.0 (1.9, 2.2) .58
Cardiopulmonary bypass time, min, median (IQR) 110 (87, 140) 103 (81, 133) .001 106 (85, 135) 106 (83, 140) 1.00
Hematocrit (%), median (IQR) 40 (36, 43) 40 (36, 42) .27 40 (36, 43) 40 (36, 43) .76
Platelets, thousands/μL, median (IQR) 207.0 (170.0, 253.0) 201.0 (168.0, 242.5) .11 250.0 (169.0, 248.0) 203.0 (169.0, 248.0) .55
Creatinine, mg/dL, median (IQR) 0.96 (0.80, 1.15) 0.96 (0.80, 1.12) .37 0.96 (0.80, 1.15) 0.95 (0.80, 1.11) .52
STS major morbidity/mortality score, %,§ median (IQR) 13.2 (8.7, 21.2) 12.3 (8.2, 21.0) .17 13 (9, 21) 12 (8, 21) .20
STS mortality score, %,§ median (IQR) 1.34 (0.74, 2.91) 1.36 (0.69, 3.08) .45 1.33 (0.74, 2.97) 1.36 (0.69, 3.05) .81

Data are presented as median (25%, 75%) for continuous variables and n (%) for categoric data. EACA, Epsilon-aminocaproic acid; TXA, tranexamic acid; CVA, cerebrovascular accident; TIA, transient ischemic attack; GP, glycoprotein; ADP, adenosine 5′-diphosphate; CABG, coronary artery bypass grafting; IQR, interquartile range; STS, Society of Thoracic Surgeons.

Data missing, 1.

Data missing, 2.

§

Data missing, 268.

Data missing, 70.